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REVIEW
Long Noncoding RNAs in the Regulation of Inflammatory
Pathways in Rheumatoid Arthritis and Osteoarthritis
Mark J. Pearson and Simon W. Jones
Introduction
It was initially envisaged that upon completion of
the Human Genome Project, our understanding of human
disease would lead to the development of abundant new
targeted therapies with which to modify disease progres-
sion or prevent disease onset. Furthermore, advances in
next-generation sequencing (NGS) have allowed for large-
scale DNA and RNA transcriptome analysis of multiple
tissue and cell types encompassing a myriad of disease
states, leading to an increased understanding of the compo-
sition and regulation of the human genome. However, as a
result of such studies, it has become increasingly apparent
that many chronic diseases are likely to be the result of the
interaction between intrinsic genes and the external envi-
ronment, which can result in modification of the DNA
sequence and have an impact on gene expression.
This understanding has led to the emergence of
the research field known as epigenetics, which includes
the analysis of DNA modifications (including methyla-
tion and histone acetylation) as well as the transcription
of noncoding RNAs (ncRNAs). Indeed, the protein-
coding elements of the human genome are now known
to be restricted to only 2% of the total genetic material
present. Initially, the remaining DNA was thought to be
mostly “junk,” but much of this so-called “genomic dark
matter” is now known to transcribe multiple families of
ncRNAs (1), many of which have been shown to modu-
late gene expression (Figure 1).
One such family of ncRNAs is the microRNA
(miRNA) family (2), which binds to and prevents the
translation of target messenger RNAs (mRNAs) (Figure
2A). Importantly, there is now overwhelming evidence
that miRNAs are regulators of the inflammatory response
(3), and several have been associated with multiple inflam-
matory diseases including osteoarthritis (OA) (3) and
rheumatoid arthritis (RA) (4).
However, recent NGS studies have now identified a
new family of ncRNAs known as long noncoding RNAs
(lncRNAs) (5), which are defined as transcripts.200 nucleo-
tides in length (Figure 1A). More than 14,000 lncRNAs have
thus far been identified in humans (6), and they are currently
subclassified, based on their position relative to protein-
coding genes (Figure 1B), as antisense lncRNAs, pseudogene
lncRNAs, enhancer RNAs, intronic lncRNAs, and long
intergenic noncoding RNAs (lincRNAs). These multiple
variants may in part explain the functional diversity that has
thus far been assigned to lncRNAs (7), including
inhibiting transcriptional machinery, functioning as
miRNA sponges, affecting miRNA stability, and epigenet-
ically modifying DNA (Figures 2B–D). Many of these
functions have been attributed to the theory that lncRNAs
form flexible scaffolds that can bind proteins and RNAs.
Notably, increasing evidence suggests that lncRNAs
are important regulators of pathologic and physiologic
processes, and evidence is now emerging to suggest that
lncRNAs are central regulators of the inflammatory
response. Therefore, we examined evidence for the role
of lncRNAs as regulators of inflammatory joint disease,
by highlighting studies that have demonstrated differen-
tial expression of lncRNAs in the inflamed joint tissue
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of patients with RA and those with OA, as well as studies
in which lncRNAs have been implicated as regulators
of known inflammatory pathways relevant to joint
pathology (Tables 1 and 2). LncRNAs are poorly con-
served across species, which has been a limitation of
studies performed to determine their function. This poor
conservation places great importance on the require-
ment to validate the function of lncRNAs in disease-
relevant human cells and tissues (8). For this reason, our
review focuses on lncRNA data generated from analysis
of human cells and tissues.
LncRNA regulation of inflammatory pathways
Inflammation is a central hallmark of RA joint dis-
ease, and evidence for inflammatory pathway dysregula-
tion and cell dysfunction has been observed in almost all
innate and adaptive immune cells. In addition, despite
OA historically being seen as a “wear and tear” disease of
cartilage, there is now substantial evidence that inflamma-
tion is also a key contributor to OA joint pathology (9).
OA synovial inflammation (synovitis) has been shown
histologically as well as by ultrasonography and magnetic
resonance imaging (10,11), and there is evidence for
increased cellular infiltration of activated B cells and T
lymphocytes and elevated levels of proinflammatory
cytokines in synovial fluid (12). Furthermore, ex vivo
stimulation of cartilage tissue with proinflammatory
cytokines mimics several pathologic features of the OA
joint (13), and inhibitors of inflammatory pathways
have modified OA disease in preclinical models (14).
As described below, we examined current evidence
for the role of lncRNAs in regulating canonical inflammatory
pathways that are relevant to inflammatory joint pathology.
Of the major signaling pathways that are known to govern
joint inflammation, 4 pathways were highlighted as having
lncRNAs associated with their regulation, namely NF-kB
signaling, the p38 MAPK pathway, the arachidonic acid
pathway, and Toll-like receptor (TLR) signaling.
NF-kB pathway. NF-kB is considered to be a mas-
ter regulator of inflammation, and its activity has been shown
to regulate the production of several proinflammatory cyto-
kines implicated in OA and RA joint pathology, including
interleukin-1b (IL-1b), IL-6, IL-17, and tumor necrosis
Figure 1. Classification of noncoding RNAs (ncRNAs) and long noncoding RNA (lncRNA) subtypes. A, LncRNAs are classified as being .200
nucleotides (nt) in length, in contrast to microRNAs (miRNAs), which are ,200 nucleotides long. B, LncRNAs are further classified by their posi-
tion relative to protein-coding genes. Intronic lncRNAs are transcribed from intronic transcription start sites (TSS) and can be in either sense or
antisense orientation. They do not intersect any exons. In contrast, antisense lncRNAs are transcribed across protein-coding exons on the opposite
strand. Long intergenic noncoding RNAs (lincRNAs) are transcribed from TSS between protein-coding genes. Pseudogenes can be classified as a
type of lincRNA and originate when a gene loses its coding ability (e.g., through a mutation). Enhancer RNAs (eRNAs) can also be considered a
type of lincRNA but are transcribed from enhancer regions (identified by the presence of high H3K4me1 histone marks). In contrast, other
lncRNAs are transcribed from regions associated with the presence of high H3K4me3 histone marks, similar to protein-coding genes.
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factor (TNF) (12,15). Therefore, inhibition of NF-kB signal-
ing has long been considered to be an attractive pathway
for developing an effective therapy for chronic inflam-
matory disorders (15). However, therapeutic targeting
of NF-kB presents a challenge, because NF-kB may
also have an antiinflammatory role and be important for
the resolution of inflammation (16). Therefore, it is
important to identify new approaches to appropriately tar-
get the proinflammatory activity of NF-kB within the joint
(17), so that systemic effects are avoided and patients are not
immunocompromised.
Thus far, several lncRNAs have been identified and
implicated in targeting different components of the NF-kB
signaling pathway (Figure 3A). Of most immediate interest
with regard to inflammatory joint disease is lincRNA-p21,
whose ability to inhibit NF-kB signaling by sequestering
RelA (the p65 subunit of NF-kB) in T cells has been dem-
onstrated following methotrexate treatment in patients
with RA. The expression of LincRNA-p21 was shown to be
up-regulated by methotrexate via a DNA-dependent pro-
tein kinase catalytic subunit–dependent mechanism (18).
Another lncRNA that has been implicated as reg-
ulating NF-kB activity is the pseudogene Lethe, which
has been shown to be expressed in fibroblasts. Functional
studies have demonstrated that Lethe interacts with and
blocks the DNA binding of RelA (p65). It is believed that
Lethe acts as part of a negative feedback loop that acts to
regulate the inflammatory response, whereby following NF-
kB activation by proinflammatory cytokines, up-regulation
of Lethe inhibits NF-kB signaling. Of interest, the tissue
expression of Lethe has been shown to be down-regulated
in aged mice (19). If the same is true in human aging, the
reduction in the expression of this potential brake on NF-
kB activity could contribute to age-associated inflammatory
joint disorders such as RA and OA. Finally, studies
conducted in human inflammation-stimulated breast epi-
thelial cells have shown that the lncRNA NKILA (NF-kB–
interacting lncRNA) binds to and blocks phosphorylation
sites on IkB, thereby inhibiting IKK-induced IkB phosphor-
ylation and NF-kB activation (20). Thus far, there are no
studies that demonstrated the functional role of lincRNA-
p21, Lethe, or NKILA in RA or OA joint tissues or cells.
Figure 2. Functional diversity attributed to long noncoding RNAs (lncRNAs). A, Noncoding microRNAs (miRNAs) are involved in posttran-
scriptional regulation of gene expression. MiRNAs bind to the 30-untranslated region of target mRNAs in the cytoplasm. Assembly of an RNA-
induced silencing complex (RISC), composed of Ago2, Dicer, and R2D2, leads to mRNA degradation. Conversely, lncRNAs can modulate gene
expression through both pretranscriptional and posttranscriptional regulation mechanisms. B, LncRNAs can act as scaffolds for the assembly of
complexes that epigenetically modify the DNA (e.g., histone acetylation and methylation), leading to modulation of transcription. C, LncRNAs
can bind to transcription factors and mediate assemblage of transcription initiation complexes, leading to modulation of transcription. D,
LncRNAs can bind to miRNAs, acting as sponges to block their activity or affecting miRNA stability.
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Table 1. Involvement of lncRNA in inflammatory pathways*
Pathway, lncRNA Tissue/cell Chromosome locus Function Author, year (ref.)
NF-kB signaling
lincRNA-p21 T cells 6p21.2 Inhibition of NF-kB following
methotrexate treatment
Spurlock et al, 2014 (18)
NKILA Epithelial cells 20q13.31 Inhibition of IkB phosphorylation Liu et al, 2015 (20)
Lethe Fibroblasts NR Inhibition of RelA DNA binding Rapicavoli et al, 2013 (19)
p38 MAPK
MALAT1 Endothelial cells 11q13.1 Reduced p38 phosphorylation
and inaction of p38 MAPK
signaling
Liu et al, 2014 (32)
Puthanveetil et al, 2015 (33)
Arachidonic acid
PACER Epithelial cells 1q31.1 Inhibition of COX-2 Krawczyk et al, 2014 (25)
Toll-like receptor
THRIL Macrophages 12q24.31 Complex formation with
hnRNPL to induce TNF expression
Li et al, 2014 (34)
IL-1b–RBT46 Monocytes 2q14 Inhibition of IL-1b and IL-8 secretion Ilott et al, 2014 (37)
LincRNA–COX-2 BMDCs 1q31.1 Up-regulation of IL-6 and down-
regulation of CCL5
Carpenter et al, 2013 (35)
NEAT1 HeLa 11q13.1 Activated by p38 leading to
expression of IL-8
Imamura et al, 2014 (36)
* LncRNA5 long-noncoding RNA; lincRNA-p215 long intergenic noncoding RNA p21; NKILA5NF-kB–interacting lncRNA; NR5 not
reported; MALAT15metastasis-associated lung adenocarcinoma transcript 1; PACER5 p50-associated cyclooxygenase 2 (COX-2) extragenic
lncRNA; THRIL5 tumor necrosis factor (TNF) and heterogeneous nuclear RNP L (hnRNPL)–related immunoregulatory lincRNA; IL-1b–
RBT465 interleukin-1b regions of bidirectional transcription 46; BMDCs5 bone marrow–derived dendritic cells; NEAT15 nuclear-enriched
abundant transcript 1.
Table 2. Evidence for the differential expression of lncRNAs in osteoarthritis and rheumatoid arthritis joint tissue*
Disease, lncRNA Tissue/cell
Chromosome
locus
Disease
expression Function Author, year (ref.)
Osteoarthritis
Hivep2-AS (CILinc01) Chondrocytes 6q23-q24 Up-regulated Suppresses IL-6, IL-8,
TNF, G-CSF, MIP-1b
Pearson et al, 2016 (26)
IL-7AS (CILinc02) Chondrocytes 8q12-q13 Up-regulated Suppresses IL-6 Pearson et al, 2016 (26)
H19 Chondrocytes 11p15.5 Up-regulated Anabolic functions Steck et al, 2012 (44)
LncRNA-CIR Chondrocytes 6q22.32 Up-regulated Promotes expression
of MMP-13 and ADAMTS-5
while inhibiting collagen and
aggrecan production
Liu et al, 2014 (51)
MEG3 Cartilage 14q32.2 Down-regulated Inversely correlated with
VEGF
Su et al, 2015 (49)
HOTAIR Cartilage 12q13.13 Down-regulated Unknown Xing et al, 2014 (41)
GAS-5 Cartilage 1q25.1 Down-regulated Increases expression of MMPs
and ADAMTS-4; induces
apoptosis
Song et al, 2014 (48),
Xing et al, 2014 (41)
LncRNA uc.343 Cartilage NR Up-regulated Regulation of HOXC8 Fu et al 2015 (50)
Rheumatoid arthritis
H19 Synovium 11p15.5 Up-regulated Increases expression of NF-kB,
IL-6, TNF
Stuhlm€uller et al, 2003 (43)
HOTAIR Synovial
fibroblasts,
osteoclasts
12q13.13 Down-regulated Increases MMP-2 and MMP-13
expression
Song et al, 2015 (42)
HOTAIR Bone
mononuclear
cells
12q13.13 Up-regulated Migration and activation of
macrophages
Song et al, 2015 (42)
LincRNA-p21 T cells 6p21.2 Down-regulated
(up-regulated
following
methotrexate
treatment)
Inhibition of NF-kB following
methotrexate treatment
Spurlock et al, 2014 (18)
* LncRNA5 long noncoding RNA; Hivep2-AS5human immunodeficiency virus type I enhancer binding protein 2AS; CILinc015 chondrocyte
inflammation–associated lincRNA 01; IL-65 interleukin-6; TNF5 tumor necrosis factor; G-CSF5 granulocyte colony-stimulating factor; MIP-
1b5macrophage inflammatory protein 1b; lncRNA-CIR5 cartilage injury–related lncRNA; MMP-135matrix metalloproteinase 13; MEG3-
5maternally expressed gene 3; VEGF5 vascular endothelial growth factor; HOTAIR5homeobox antisense intergenic RNA; GAS-55 grow
arrest–specific 5; NR5not reported; HOXC85homeobox C8.
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Arachidonic acid pathway. Arachidonic acid
metabolites (prostaglandins and leukotrienes) are known
mediators of the inflammatory response (21), and several
have been shown to be differentially expressed in the
joints of patients with either OA or RA (22). Therefore,
targeted inhibition of the arachidonic acid pathway has
long been considered to be an important area of research
for developing a therapeutic agent that combats joint
inflammation and pain. Indeed, inhibition of the prosta-
glandin synthase (cyclooxygenase [COX]) enzymes is the
basis for the mode of action of nonsteroidal antiinflamma-
tory drugs (NSAIDs) such as ibuprofen (23) and selective
PTGS-2 (prostaglandin-endoperoxide synthase 2)/COX-2
inhibitors such as valdecoxib (24), which have shown effi-
cacy in reducing joint inflammation in several clinical
trials.
Of importance, therefore, was the recent finding
that the expression of PTGS-2 was positively regulated
by the lncRNA p50-associated COX-2–extragenic RNA
(PACER) (25) (Figure 3B). PACER was shown to bind
to and remove the repressive action of the p50 homodimer
(of NF-kB) at the COX-2 promoter, leading to activation
of COX-2 gene expression. Furthermore, we recently
observed that the expression of PACER was associated
with the IL-1b–mediated inflammatory response in pri-
mary human OA chondrocytes and was differentially
expressed in human OA cartilage compared with non-OA
cartilage (26).
Unfortunately, long-term administration of non-
selective NSAIDs is associated with gastrointestinal tox-
icity (27), while selective COX-2 inhibitors increase the
risk of cardiovascular adverse events (28), attributed to a
Figure 3. Functional long noncoding RNAs (lncRNAs) in inflammatory pathways. A, Canonical NF-kB signaling. The lncRNA NKILA (NF-
kB–interacting lncRNA) blocks the Ikba phosphorylation site, preventing its activation. The lncRNAs Lethe and long intergenic noncoding
RNA p21 (lincRNA-p21) both bind to RelA and prevent NF-kB binding to NF-kB response elements. B, Arachidonic acid pathway. The
lncRNA p50-associated cyclooxygenase 2 (COX-2)–extragenic RNA (PACER) binds to and removes the repressive action of the p50 homodimer
at the COX-2 promoter, leading to activation of COX-2 gene expression. C, P38 MAPK signaling. The lncRNA MALAT1 (metastasis-associated
lung adenocarcinoma transcript 1) inhibits p38 phosphorylation. Adenine-rich elements (AREs) in mRNA transcripts are stabilized via down-
stream MAPK-activated protein kinase 2 (MK-2) activation. D, Toll-like receptor (TLR) signaling. The lncRNAs THRIL (tumor necrosis factor
[TNF] and heterogeneous nuclear RNP L [hnRNPL]–related immunoregulatory lincRNA) and lincRNA–COX-2 form complexes with
hnRNPLs, which then bind to and activate the promoters of proinflammatory cytokines TNF and CCL5, respectively. The lncRNA NEAT1
(nuclear-enriched abundant transcript 1) binds to SFPQ (splicing factor proline/glutamine-rich) and relocates it to paraspeckle bodies, relieving
its repression of the interleukin-8 (IL-8) promoter. The lncRNA IL-1b–RBT46 (IL-1b regions of bidirectional transcription 46) is induced by
TLR-4 signaling and promotes induction of IL-8 and IL-1b via an as-yet unknown mechanism. NEMO5NF-kB essential modulator;
PGG25 prostaglandin G2; TXA25 thromboxane A2; MMP-135matrix metalloproteinase 13.
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resulting imbalance between thromboxane T and prosta-
cyclin levels. Therefore, identifying new regulators of
prostaglandin production such as PACER is important,
because it may lead to new targeted approaches that
are capable of selectively inhibiting the production of
inflammation-associated arachidonic acid metabolites
without any resulting toxicity.
MAPK signaling. Several studies have provided
evidence that the p38 MAPK pathway is central to medi-
ating both the production of proinflammatory cytokines
and their signal transduction in the joint (13). Further-
more, p38 small molecule inhibitors have shown efficacy
in both reducing cartilage degeneration in OA preclini-
cal models (29,30) and reducing inflammatory pain in
RA models (14,31), although clinical trials of p38 inhibi-
tors in patients with RA have thus far failed to meet clin-
ical end points.
With regard to lncRNA regulation of the p38 path-
way, recent studies suggest the involvement of MALAT1
(metastasis-associated lung adenocarcinoma transcript 1)
(32) (Figure 3C). MALAT1 is one of the most abundantly
expressed lncRNAs, with high levels of conservation
across multiple tissue types. It has previously been well-
characterized in cancer, in which it is a transcription regula-
tor implicated in cell cycle control and metastasis. How-
ever, Liu and colleagues have now highlighted MALAT1
cross-talk with p38 MAPK as being pathogenic in diabetes
mellitus. MALAT1 is believed to activate p38 MAPK,
because small interfering RNA (siRNA)–mediated knock-
down of MALAT1 reduced p38 phosphorylation (32). Fur-
thermore, MALAT1 expression has been shown to be
implicated in inflammation, again in diabetes mellitus
under hyperglycemic conditions; in this setting, it was
shown to contribute to increased IL-6 expression and reac-
tive oxygen species generation (33).
TLR signaling. Innate immune cells such as
macrophages and neutrophils are present in the inflamed
joints of patients with RA and those with OA, and it is
known that TLR signaling plays a key role in the recruit-
ment and activation of these cells. Therefore, understand-
ing the regulation of cytokine and chemokine signaling by
these cells will provide greater clues regarding the onset
and maintenance of chronic inflammation within the joint.
THRIL (TNF and heterogeneous nuclear RNP L
[hnRNPL]–related immunoregulatory lincRNA) was re-
cently identified in macrophages as an lncRNA that could
form a complex with hnRNPL within the nucleoplasm (Fig-
ure 3D). HnRNPs are known to be important for the pro-
cessing, function, and stabilization of mRNAs. Critically, it
was demonstrated that the THRIL–hnRNPL complex binds
to the promotor of TNF and induces its expression following
TLR-2 activation (34).
Carpenter and colleagues (35) identified an lncRNA
(lincRNA–COX-2) that is located in close proximity to the
PTGS-2 gene but, unlike the aforementioned PACER, this
lncRNA had no functional interaction with PTGS-2.
Instead, lncRNA–COX-2 was shown to be up-regulated
following activation of the TLR-2 pathway (Figure 3D).
Furthermore, following knockdown of lincRNA–COX2
and under the challenge of a synthetic TLR-2 antago-
nist, expression of IL-6 became undetectable, while CCL5
expression increased. Similarly to THRIL, lincRNA–COX-2
forms complexes with hnRNPs, specifically hnRNP A/B and
hnRNP A2/B1, and the formation of such complexes has
been shown to modulate target gene expression.
Activation of TLR-3 has been shown to induce an
lncRNA referred to as NEAT1 (nuclear-enriched abun-
dant transcript 1). NEAT1 was shown to bind to a repres-
sor of IL-8 transcription known as SFPQ (splicing factor
proline/glutamine-rich) and relocate it to paraspeckle
bodies (Figure 3D), resulting in IL-8 transcriptional acti-
vation (36). Ilott and colleagues (37) demonstrated that
TLR-4 activation in monocytes up-regulated expression
of an lncRNA known as IL-1b–RBT46 (IL-1b regions of
bidirectional transcription 46). IL-1b–RBT46 shares a
promoter with the IL-1b–coding gene, and following
pathway activation, expression of both the lincRNA and
the IL-1b gene is induced (Figure 3D). Locked nucleic
acid (LNA)–mediated knockdown of IL-1b–RBT46 led
to a decrease in IL-1b mRNA expression, suggesting that
the lincRNA promotes expression of the gene. A further
consequence of IL-1b–RBT46 knockdown was a reduc-
tion in the expression of IL-8, a well-defined neutrophil
chemoattractant.
The lncRNAs described above represent a pool
of lncRNAs that have not yet been associated with
inflammatory joint disease. However, given their preva-
lence in the regulation of central pathways of inflamma-
tion, studies determining their expression in joint tissue,
and their relationship to OA and/or RA joint pathology
would appear to be important.
The significance of genetic variations in the
sequences of lncRNAs is currently not well understood
and to date has been little studied. There is evidence that
large alterations such as chromosomal rearrangements
can affect lncRNA expression (38). However, as illus-
trated by the functional studies highlighted in this review,
lncRNA function may be determined largely by its sec-
ondary structure, through binding to proteins and RNA.
Therefore, smaller mutations and genetic variations such
as single-nucleotide polymorphisms (SNPs) may have lit-
tle effect on lncRNA function. It is conceivable that SNPs
could alter lncRNA function by altering the lncRNA sec-
ondary structure or causing alternative splicing of the
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lncRNA. Indeed, there is evidence that SNPs in the chro-
mosomal region that harbor the lncRNA ANRIL are
associated with susceptibility to cardiovascular disorders
(39). However, it is not currently known whether these
SNPs have an impact on the functional role of the ANRIL
lncRNA or simply affect its expression. Predominantly,
therefore, studies have thus far linked lncRNA to disease
by expression analysis.
LncRNA expression in inflammatory OA and RA joint
tissue
Transcriptional analyses by both NGS and micro-
array have identified several lncRNAs that are differen-
tially expressed in inflamed joint tissue. Thus far,
studies using OA patient samples have focused on carti-
lage tissue, while in RA disease other perijoint tissues
such as synovium and subchondral bone have been
interrogated.
One lncRNA that has been shown to be differen-
tially expressed in both OA and RA joint tissue is HOTAIR
(homeobox antisense intergenic RNA). Located on chro-
mosome 12, HOTAIR was the first lncRNA to be charac-
terized and has been shown to interact with polycomb
repressive complex 2, which regulates the chromatin state,
and the histone demethylase, lysine-specific demethylase 1.
As such, it regulates epigenetic changes within its target
transcripts (40).
In OA cartilage, compared with non-OA cartilage,
HOTAIR was shown to be up-regulated (41), although as
yet its function in cartilage tissue or in isolated chondro-
cytes has not been reported. Song et al (42) have also iden-
tified differential expression of HOTAIR in RA perijoint
tissues, namely synovial fibroblasts, osteoclasts, and bone
mononuclear cells. Of note, Song et al found that the
function of HOTAIR differed depending on the RA cell
studied. For example, in RA synovial fibroblasts and oste-
oclasts, HOTAIR expression was lower than in controls,
and its overexpression decreased the expression of matrix
metalloproteinase 2 (MMP-2) and MMP-13. In contrast,
HOTAIR was up-regulated in RA bone mononuclear
cells, where it functioned to facilitate macrophage activa-
tion and migration toward the joint.
Another lncRNA for which differential expression
has been reported in inflamed joint tissue is H19. H19
lncRNA has been demonstrated to be highly expressed in
RA synovial tissue (43) and in OA cartilage (44). Previous
studies have demonstrated that H19 is a developmental
reservoir of the 2 miRNA-675 (miR-675) family members,
miR-675-p3 and miR-675-p5, which have been shown to
regulate type II collagen expression and mediate cellular
development in multiple tissues (45–47). Of interest,
numerous studies have demonstrated that H19 controls
the expression of several genes that are part of the
imprinted gene network, a series of parentally inherited
genes the expression of which is epigenetically determined
within the sperm or oocyte. Such “imprinting disorders”
have been linked to a number of human pathologies. Cur-
rently, inflammatory disease is not known to be affected
by imprinting disorders, but given the inheritability of RA
and other inflammatory diseases, studies that investigate
the role of H19 in determining epigenetic susceptibility to
disease could be of interest.
As previously mentioned, lncRNA analysis in OA
has focused primarily on cartilage tissue, and the lncRNA
GAS-5 (growth arrest–specific 5) (48) and maternally
expressed gene 3 (49) have been reported to be down-
regulated in OA-diseased cartilage. Fu and colleagues (50)
performed microarray analysis and identified 4,714
lncRNAs that were differentially expressed in OA cartilage
compared with non-OA cartilage. Although in the current
study we did not perform any modulation of lncRNA
expression to determine lncRNA function, expression cor-
relation patterns were used to predict candidate lncRNA-
regulated genes. This analysis highlighted lncRNA uc.343,
which was up-regulated in OA cartilage, as regulating in
cis the expression of homeobox C8 (50), and that many of
the differentially expressed lncRNAs worked in concert
with the transcription factor Sp1 to modulate expression of
trans target genes.
In a separate study, microarray analysis was per-
formed to identify a lncRNA with a specific role in the
degradation of the cartilage matrix, named cartilage
injury–related lncRNA (lncRNA-CIR). LncRNA-CIR
was shown to be up-regulated in OA cartilage compared
with non-OA cartilage, and siRNA-mediated knock-
down of its expression resulted in increased expression
of collagen and aggrecan accompanied by reduced
expression of MMP-13 and ADAMTS-5 (51).
Furthermore, we recently identified lncRNAs asso-
ciated with the IL-1b–mediated inflammatory response in
primary human OA chondrocytes that were also differen-
tially expressed in diseased OA cartilage. Of particular
note were human immunodeficiency virus type I enhancer
binding protein 2S (Hive2pAS) and IL-7AS, 2 intergenic
lncRNAs proximal to the Hivep2 and IL-7 protein-coding
genes, respectively (26). Both Hive2pAS and IL-7 AS
were observed to be up-regulated in both knee OA and
hip OA cartilage compared with non-OA control cartilage
(26). Furthermore, locked nucleic acid (LNA)–mediated
knockdown of Hive2pAS and IL-7AS gene expression in
human chondrocytes resulted in an increase in the produc-
tion of proinflammatory cytokines, including IL-6 (26),
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suggesting that these lncRNAs may function to control
aberrant joint inflammation.
Conclusions
LncRNA research in inflammatory joint disease is
very much a nascent field. However, several lncRNAs
have now been identified as being either differentially
expressed in diseased joint tissue or as candidate central
regulators of inflammatory pathways relevant to joint
pathology. Therefore, future studies to determine the
functional role and mode of action of these disease-
associated lncRNAs will be insightful, as will joint tissue
expression profiling of lncRNAs for which functional roles
within key inflammatory pathways have been determined.
To this end, it will be important to conduct further trans-
criptomic analysis of joint tissues (including subchondral
bone, cartilage, and synovium) in which diseased joint tis-
sues are compared with age-matched noninflammatory
control joint tissue and to conduct functional mode-of-
action studies in disease-relevant cells.
It should be noted that, currently, expression analy-
sis of lncRNAs in the joint tissue of patients with other
inflammatory joint diseases including gout, psoriatic arthri-
tis, and juvenile idiopathic arthritis has not yet been
reported. Clearly, such studies could also prove to be infor-
mative in building a broader pool of inflammatory joint
disease–associated lncRNAs. Indeed, because inflamma-
tory joint diseases share several common pathways,
such studies are likely to identify lncRNAs that are dys-
regulated across multiple inflammatory joint disorders.
Such findings will add to the recent paradigm shift in
our understanding of the dysregulation in chronic dis-
ease, whereby the disease is no longer classified solely
by its gross pathology but by the involvement of a par-
ticular dysregulated pathway.
It is currently too early to determine whether
disease-modifying therapeutic agents could be devel-
oped that are designed to directly target and modulate
lncRNA function. Recent progress has been achieved
using siRNA-mediated RNA interference–based thera-
peutics, whereby targeted knockdown of TNF (52) or NF-
ŒB (53) has modified disease progression in animal models
of RA and OA. Therefore, it is conceivable that lncRNAs
could provide a new class of targets for RNA interference–
based therapeutics. Regardless, ultimately determining the
mode of action of lncRNAs that regulate inflammatory
pathways and determining their relationship to joint
pathology will provide a better understanding of how
inflammation is epigenetically regulated within the joint.
This improved understanding will likely be important in
aiding the identification of new targets for therapeutic inter-
vention as well as in identifying at-risk patient populations.
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